Risk Assessment in Drug Development (or How much of compound X is safe? ) (EYP 2006) Colin Fish
|
|
- Horatio Fox
- 6 years ago
- Views:
Transcription
1 Risk Assessment in Drug Development (or How much of compound X is safe? ) (EYP 2006) Colin Fish
2 History All substances are poisons; there is none which is not a poison. The right dose differentiates a poison from a remedy. Philippus Aureolus Theophrastus Bombastus von Hohenheim- Paracelsus ( )
3 Comparison of lethal doses of well known agents Agent LD50 (mg/kg) Ethyl alcohol 10,000 Sodium chloride 4,000 Ferrous sulphate 1,500 Morphine sulphate 900 Phenobarbital sodium 150 Picrotoxin 5 Strychnine sulphate 2 Nicotine 1 d-tubocurarine 0.5 Hemicholinium Tetrodotoxin 0.10 Dioxin (TCDD) Botulinum toxin From Casarett and Doull s Toxicology
4 Principles For new drugs, Preclinical Safety Assessment conducts a set of animal and in vitro studies with the active ingredient Defined by regulatory guidelines General expectation is to induce toxicity or show diligent attempts to maximise exposure Purpose: identify and characterise hazards establish dose-response and exposure-response relationships allow informed assessment of risks
5 isk Assessment: Pre-Test his scenario has high risk. (Agree/Disagree)
6 HAZARD - the inherent potential for harm RISK - the probability of harm under specific conditions
7 Risk Assessment and Drug Development Hazard Identification Scientific Processes Risk Assessment Process Hazard Characterisation Exposure Assessment Dose Response Science and Policy Risk Evaluation Modified from Haschek and Rousseaux Toxicologic Pathology Risk Management Technology and Social Decisions
8 Hazard identification and characterisation Cascade of studies, based on: Regulatory guidelines Internal harmonisation Acceptability to internal and external ethics boards Scientific rationale Not as simple as just following a recipe
9 Core Hazard Identification Studies Before Candidate Selection (CS) Early Safety Prediction ( target liability, QSAR) Compound activity profiling (e.g., receptors, enzymes) Screens for genetic toxicity and arrhythmogenic potential Acute in vivo toxicology (e.g., rat 7-day toxicology study) CS to First Time in Man (FTIH) Definitive genetic toxicity tests Dose-range and definitive day toxicology Safety Pharmacology (CV, CNS, respiratory) FTIH to Proof-of-Concept (PoC) 3 to 12 month toxicology Reproductive toxicology (fertility, teratology) PoC to Launch Immunotoxicology Juvenile / postnatal development studies 2 year rodent carcinogenicity studies Additional specialized studies to characterize hazards Often modified by prior knowledge
10 Risk Assessment Multifactorial, multidisciplinary approach: Nature of the hazard (i.e. seriousness of the toxicity) Dose-response and exposure-response relationship Therapeutic Index ( safety margin ) Mechanism species specificity / relative sensitivity metabolism / tissue distribution Reversibility Availability of early markers Target population Risk/benefit ratio (depends on target disease) Comparison with existing therapy concept of acceptability of class effects
11 Clinical trials Drug development: clinical trials are progressive: Clinical trials sequence: Phase I: safety and tolerability in normal volunteers (small numbers, closely monitored) Phase II: safety and dose ranging / efficacy in patient volunteers (small numbers, closely monitored) Phase III: definitive efficacy in patients (large numbers, more extensive)
12 Progressive preclinical support Extended duration and scale of clinical trials: Studies to support Phase I and II (and III in US only) Duration of Clinical Duration of Repeated Dose Toxicity Studies Trial Rodent Non-rodent Single dose 2-4 weeks 2 weeks Up to 2 weeks 2-4 weeks 2 weeks Up to 1 month 1 month 1 month Up to 3 months 3 months 3 months Up to 6 months 6 months 6 months More than 6 months 6 months 6-9 months From ICH, topic M3
13 Importance of drug measurements Animal and human Sequence of blood samples at intervals after dose Limit of quantification required may depend on dose µg/ml ng/ml pg/ml For some drugs, total administered dose in man may be 25µg For some study types (e.g., PET biodistribution studies), dose might be <10µg May also need to track metabolites that are >10% of circulating drug-related material
14 Use of exposure measurements Exposure: plot for single animal Plasma concentration C max Area under curve (AUC) Time: 0 hours 12 hours 24 hours
15
16 Principles Prime focus is on the drug itself, and safety in volunteers and patients Also look at: impurities, extractables, solvents, degradation products, intermediates, metabolites etc safety of manufacturing staff, animal dosing technicians etc implications for accidental or deliberate overdose
17 Typical Sources of Impurities Starting materials Intermediates Processing Formulation Dosing devices Sterilisation Excess materials By-products Drug substance Drug Product Catalysts Storage? Solvents Impurities Excess reagents Starting materials By-products etc Leachables Degradation products
18 ICH Guidelines Some ICH guidance exists and is contained under Quality (Q) Topics - i.e., those relating to chemical and pharmaceutical Quality Assurance. Q3A Q3B Q3C Impurities in Drug Substances Impurities in Drug Products Residual Solvents Official ICH webpage:
19 Q3A(R): Impurities in New Drug Substances Provides information on the qualification of impurities in new drug substances produced by chemical synthesis Applies to NDAs/MAAs and, retrospectively, to marketed drugs Maximum daily dose Qualification Threshold Identification Threshold 2 g/day 0.15% 0.10 % or 1 mg TDI 1,2 or 1 mg TDI 1,2 >2g/day 0.05% 0.05% 1 TDI = Total daily intake 2 Whichever is lower Note: Does not apply to biological or biotechnological substances - more specialised guidelines are available. Revised version adopted in EU - Feb 02
20 Genotoxic impurities Could argue there is no safe dose of a genotoxic agent (especially gene mutagens) FDA has asked for 1 ppm limit in some cases Recent EU guidance on genotoxic impurities Draft EMEA guideline (see Document ref: CPMP/SWP/5199/02 Concept of threshold of toxicological concern 1.5µg total daily dose for life considered safe Suggestions of flexibility for short duration of treatment
21 Genetic toxicology Perspective on in vitro Positives Cytotoxicity Mutation frequency Increase Mutation frequency Increase Cytotoxicity Dose Dose LOW CONCERN HIGH CONCERN
22 Genotoxic impurities the conundrum 1.5ug daily dose, in a 50mg/day drug = 0.003% But according to ICH Q3A(R) threshold for identification of impurities is 0.1% There might be impurities below the threshold for identification that might be genotoxic but remain untested and not controlled to 1.5ug daily dose
23 Genotoxic impurities the conundrum Solution: assessment of synthetic route and chemical structure for potential impurities and degradation products Screening of predicted structures in silico for potential genotoxicity Analytical issues: Have to work up sensitive assays for theoretical impurities, to prove they are not there! Chemistry issues: If there are suspect impurities, they have to be controlled
24 Genotoxic impurities the conundrum Other ways out: Less problematic for low dose drugs for a 25ug/day drug anything <6% will be below 1.5ug limit Others: might show that amount potentially present does not significantly add to background exposure Example: formaldehyde Classified as probable human carcinogen and as a likely mutagen, but EPA limit in drinking water 1ppm 1 litre of water might contain 1mg formaldehyde Also can be formed from aspartamine A can of diet cola could contain >1.5mg
25 Principles
26 Principles
27 Principles
28 Principles
29 Backup slides
30 Q3B(R): Impurities in New Drug Products Degradation products of the active ingredient on storage Reaction products of the active ingredient with an excipient, container or closure system Maximum daily dose Qualification Threshold < 10 mg 1% or 50μg TDI 10 mg mg 0.5% or 200 μg TDI >100 mg - 2 g 0.2% or 3 mg TDI > 2g 0.15% Note: Less stringent than Q3A because easier to attain lower LOD/LOQ in drug substance, and because degradants are more likely to be similar to parent or metabolites. Revised version adopted in EU - Mar 03
31 Q3C: Residual Solvents Solvents have no therapeutic benefit But often critical part of synthesis as can enhance yield, or determine some characteristics (eg, crystal form, purity + solubility) Remove or limit content sufficiently in order to meet product specification good manufacturing practices safety requirements Three categories based on their safety (i.e. Permissible Daily Exposures ) Adopted in EU Sept 97. Also see CPMP/QWP/450/3 Apr 03
32 Categories of Solvent Class 1: unacceptable toxicity (includes known carcinogens) should be avoided unless product gives significant therapeutic benefit (anti-cancer) e.g. benzene (2ppm), carbon tetrachloride (4ppm) Class 2: irreversible toxicity including neurotoxicity, teratogenicity and non-genotoxic carcinogens, exposure limited to <50 mg/day (5000ppm), eg, cyclohexane, pyridine, methanol Class 3: low toxicity, exposure should be limited to 50 mg/day, but higher exposure may be justifiable on case by case basis eg acetic acid, ethanol, DMSO
33 Permissible Daily Exposures (PDE) The maximum acceptable daily intake of residual solvent in pharmaceutical products Literature reviewed and NOEL (or LOEL) from most relevant toxicity studies used to calculate PDE, where: PDE = NOEL x Weight adjustment F1 x F2 x F3 x F4 x F5 The weight adjustment assumes a standard 50kg patient Connelly et al, Pharmeuropa, 1997, 9 (1 - Suppl.) S1-68
34 Metals / Catalysts Draft CPMP/EFPIA guideline (CPMP/SWP/4446-2nd version released for consultation in June 02) Acceptable limits for residual metals arising from use of catalysts in synthesis of pharmaceuticals (e.g. Ni, Cu, Cr) As no therapeutic benefit, limit on safety & quality-based criteria Being developed using same rationale as for Q3C (i.e. PDE s - but taking dietary exposure into account) Not yet considered by ICH, but good starting point if needed If not listed, use 10 ppm default, unless data suggests otherwise Available on EMEA website
35 Metals / Catalysts Concentration limits (ppm) Elements Oral Parenteral Pt, Pd, Ir, Rh, Ru, Os 5 (group) 0.5 (group) Mo, V, Ni, Cr Cu, Mn Zn, Fe If 2 or more present, the total oral limit should not exceed 20 ppm; and parenteral 2 ppm For intakes >10 g/day, reduce limits pro rata Group limit applies for platinoids. If 2 or more are present, the group conc limit is applied to the total amount For other routes of administration use parenteral values, unless absorption will never exceed oral absorption, in which case use oral value
Regulation of Genotoxic and Carcinogenic Impurities in
Regulation of Genotoxic and Carcinogenic Impurities in Pharmaceuticals Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT
More informationGeneral Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.
General Chapter/Section: Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No. of Commenters: 18 Editorial changes suggested by commenters have been reviewed by
More information232 ELEMENTAL IMPURITIES LIMITS
BRIEFING 232 Elemental Impurities Limits, USP 39 page 268. This chapter is being revised to address comments received and to further align this chapter with ICH Q3D. USP s Elemental Impurities Expert Panel
More informationPQRI PODP Extractables & Leachables Workshop Leachable Evaluation of a Container Closure System - What to do When Above the Threshold
PQRI PODP Extractables & Leachables Workshop Leachable Evaluation of a Container Closure System - What to do When Above the Threshold William P. Beierschmitt, PhD, DABT, FATS Drug Safety Research and Development
More informationConverting between PDEs and Concentration Limits
Module 7 Converting between PDEs and Concentration Limits ICH Q3D Elemental Impurities Disclaimer: This presentation includes the authors views on Elemental Impurities theory and practice. The presentation
More informationOverview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017
Overview of USP General Chapters and Prescription/Non-Prescription Stakeholder Forum October 19, 2017 Introduction Periodic review of existing general chapters Typically an approximately 5
More informationpresents Introduction to Toxicology and its Role in Green Chemistry
presents Introduction to Toxicology and its Role in Green Chemistry August 6, 2013 12:00 PM 1:00 PM ET Disclaimer: The Michigan Green Chemistry Clearinghouse (MGCC) is committed to providing webinars that
More informationIMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS PDE FOR CUMENE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE DRAFT CONSENSUS GUIDELINE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Released for
More informationOrganic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017
Organic Impurities in Drug Substances and Drug Products Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017 Potential sources of drug impurities during development AAPS PharmSciTech,
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationDr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013
The 7 truths of impurities and their reference standards FDA's and other regulators' viewpoints and further stories (Part 1) Dr. Christian Zeine LGC Standards GmbH Webinar Series 2013 July 2013 Quick guide
More informationICH guideline Q3D (R1) on elemental impurities
1 2 3 16 May2018 EMA/CHMP/ICH/353369/2013 Committee for Human Medicinal Products 4 5 Step 2b 6 Transmission to CHMP 26 April 2018 Adoption by CHMP for release for consultation 26 April 2018 Start of consultation
More informationToxicology in the workplace
Industrial Safety Series Toxicology in the workplace Dr. Ir. Yulianto S Nugroho, MSc. Department of Mechanical Engineering University of Indonesia Outline of talk Introduction Route of Body Entry Dose-response
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationThreshold Establishment and Rationale. Douglas J Ball, MS, DABT Research Fellow Pfizer Worldwide R&D
Threshold Establishment and Rationale Douglas J Ball, MS, DABT Research Fellow Pfizer Worldwide R&D 1 Objectives Basic Definitions Background on the use of safety thresholds in risk assessment Application
More informationToxicological tool. Sarah O Meara, PhD, MSc PharmMed Non-clinical Assessor. GMP Conference 12 th November 2014
Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities Toxicological tool Sarah O Meara, PhD, MSc PharmMed
More informationConcepts in Toxicology
Concepts in Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho Learning Objectives Define toxicology and toxicity. Discuss different types of toxic responses. Explain how toxicants are classified.
More informationDevelopment of Genotoxic Impurities Control in Active Pharmaceutical Ingredient
( 322002) (active pharmaceutical ingredient API) R284.1 A 1007-7693(2015)01-0119-08 DOI: 10.13748/j.cnki.issn1007-7693.2015.01.032 Development of Genotoxic Impurities Control in Active Pharmaceutical Ingredient
More informationEnvironmental Law and Policy Salzman & Thompson
Environmental Law and Policy Salzman & Thompson Ch.6/7: Regulating Toxic Substances HWR415/515 The University of Arizona 2013 1 Summary I. The Difficulties of Regulating Toxic Substances A. Is Tolerable
More informationPart 2. Chemical and physical aspects
Part 2. Chemical and physical aspects 12. Chemical and physical aspects: introduction 12.1 Background information used The assessment of the toxicity of drinking-water contaminants has been made on the
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationUSP <232> and <233> Understanding Your Path to Compliance with the New Elemental Impurity Chapters. Steve Wall Agilent Technologies
USP and Understanding Your Path to Compliance with the New Elemental Impurity Chapters Steve Wall Agilent Technologies Outline, USP - USP Chapter - Chapter Limits -
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG)
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) POINTS TO CONSIDER ON NON-CLINICAL SAFETY OF HOMEOPATHIC MEDICINAL PRODUCTS OF BOTANICAL, MINERAL AND CHEMICAL ORIGIN DISCUSSION IN THE HMPWG April 2002
More informationPrinciples of Toxicology: The Study of Poisons
Principles of Toxicology: The Study of Poisons Elizabeth Casarez Department of Pharmacology and Toxicology University it of Arizona The study of the adverse effects of a toxicant on living organisms Adverse
More informationProf. Marina Heinonen University of Helsinki Member of the NDA Panel and EFSA s WG on Novel Foods
Guidance on Novel Foods Composition, production process and specification Prof. Marina Heinonen University of Helsinki Member of the NDA Panel and EFSA s WG on Novel Foods Info-Session 06 March 2017 Parma
More informationANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationThe Islamic University of Gaza- Civil and Environmental Engineering Department Public Health (EENV-5325) Lecture 8: Toxicology.
The Islamic University of Gaza- Civil and Environmental Engineering Department Public Health (EENV-5325) Lecture 8: Toxicology By Husam Al-Najar Definition of Toxicology: The study of the adverse effects
More informationGenotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area
Genotoxicity Testing Strategies: application of the EFSA SC opinion to different legal frameworks in the food and feed area Juan Manuel Parra Morte. Pesticides Unit. EFSA. 19th Annual Conference of the
More information1st SETAC Europe Special Science Symposium
1st SETAC Europe Special Science Symposium Integrated Testing Strategies for REACH Brussels, October 23-24, 2008 Thresholds of Toxicological Concern (TTC): Human Toxicology H. Greim Technical University
More informationUse of TTC and Human Relevance George E. N. Kass, PhD
Use of TTC and Human Relevance George E. N. Kass, PhD Future Challenges in Developing Assessment Methodologies for Human Health Effects Tokyo, 14 November 2018 Disclaimer The views, thoughts and opinions
More informationType II variation. Public Assessment Report for the suspension of. Palfium 5 mg tablets. (dextromoramide) NL License RVG: 03170
Type II variation Public Assessment Report for the suspension of Palfium 5 mg tablets (dextromoramide) NL License RVG: 03170 Date: 14 September 2015 This module reflects the scientific discussion for the
More informationINTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE Q3D(R1)
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GUIDELINE FOR ELEMENTAL IMPURITIES (R1) Draft version Endorsed on 18 May 2018
More informationSCIENTIFIC / TECHNICAL REPORT submitted to EFSA
SCIENTIFIC / TECHNICAL REPORT submitted to EFSA Applicability of thresholds of toxicological concern in the dietary risk assessment of metabolites, degradation and reaction products of pesticides 1 Prepared
More informationGENERAL PRINCIPLES OF TOXICOLOGY
GENERAL PRINCIPLES OF TOXICOLOGY Laboratory of toxicology Department of Pharmacology and Toxicology College of Pharmacy, University of Baghdad 2015 TOXICOLOGY - PRACTICAL SYLLABUS 2015 General Principles
More informationarea of toxicology: The following are examples of some LD50 Values LD50 Dose Response Curve Sample
Chemical hazards are associated with a significant number of high profile food safety alerts, recalls and withdrawals. The principles of HACCP require chemical hazards to be considered during the hazard
More informationDose and Response for Chemicals
Dose and Response for Chemicals 5 5 DOSE AND RESPONSE FOR CHEMICALS All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy. Paracelsus, 16th
More informationPremarket Review. FFDCA Section 201(s) FFDCA Section 201(s) (cont.)
FFDCA Section 201(s) intended use of which results or may reasonably be expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food Mitchell
More informationJaneen A. Skutnik-Wilkinson ICH Topic co-creator EWG Team Member
Janeen A. Skutnik-Wilkinson ICH Topic co-creator EWG Team Member April 2012 1 Metal Impurities (aka Heavy Metals) STUCK for at least 10 years No Harmonised guidance in ICH or other regions Establish appropriate
More informationApplicators and Pesticide Toxicity
Applicators and Pesticide Toxicity Moire Creek Manager, Toxicology Valent USA Corporation Toxicology: The Science of Poison All substances are poisons; there is none which is not a poison. The right dose
More informationEuropean Public MRL assessment report (EPMAR)
8 September 2015 EMA/CVMP/632934/2014 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Propyl 4-hydroxybenzoate and its sodium salt (all food producing
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/016/95-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS COLISTIN SUMMARY REPORT (1) 1. Colistin
More informationCross Contamination & the EU GMP Guide. Bryan J Wright July 2017
Cross Contamination & the EU GMP Guide Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline PICs GMP (v13) and Cross Contamination (CC) EU GMP Guide changes to Chapters 3 & 5 Other related EU regulatory
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1 Introduction This is an application for a CHMP Scientific Opinion in accordance with Article 58 of Regulation (EC) No 726/2004, in the context of cooperation with the World Health
More informationPublic Assessment Report. Scientific discussion. Celecoxib Apotex 100 mg and 200 mg, capsules, hard (celecoxib) NL/H/2760/ /DC
Public Assessment Report Scientific discussion Celecoxib Apotex 100 mg and 200 mg, capsules, hard (celecoxib) NL/H/2760/001-002/DC Date: 29 April 2014 This module reflects the scientific discussion for
More informationPQRI PODP Extractables & Leachables Workshop Derivation of the Parenteral Safety Concern Threshold (SCT)
PQRI PODP Extractables & Leachables Workshop Derivation of the Parenteral Safety Concern Threshold (SCT) Presented by: Douglas J Ball, MS, DABT Toxicology Consultant April 2018 Agenda TTC Cramer Classification
More informationUse of Bridging Justifications to Support the Safety of Excipients in Generic Drug Products
Use of Bridging Justifications to Support the Safety of Excipients in Generic Drug Products Sruthi King, Ph.D. Pharmacology/Toxicology Team Leader Division of Clinical Review, Office of Generic Drugs Center
More informationRisk Assessment Report on Tris (nonylphenyl)phosphite (TNPP)
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON HEALTH AND ENVIRONMENTAL RISKS SCHER
More informationPublic Assessment Report. Scientific discussion. Abstral, sublingual tablet 50, 100, 200, 300, 400, 600 and 800 μg. (Fentanyl citrate)
Public Assessment Report Scientific discussion Abstral, sublingual tablet 50, 100, 200, 300, 400, 600 and 800 μg (Fentanyl citrate) SE/H/575/01-07/DC This module reflects the scientific discussion for
More informationThreshold of Toxicological Concern (TTC):
Threshold of Toxicological Concern (TTC): Introduction into the Tiered TTC Concept and regulatory status globally Dr Kirstin Kosemund, Procter & Gamble, Central Product Safety Eurotox 2015 CEC, September,
More informationU.S. Requirements for Dietary Supplement Ingredients and USP <2232> Elemental Impurities Is Your Company Ready for Implementation?
U.S. Requirements for Dietary Supplement Ingredients and USP Elemental Impurities Is Your Company Ready for Implementation? Priscilla Zawislak NIA-West, Ojai, CA May 28, 2015 1 Outline Ø U.S. Regulatory
More informationPRINCIPLES OF TOXICOLOGY
PRINCIPLES OF TOXICOLOGY BY PUROHIT TEJENDRA J M.V.Sc. First Semester Major Advisor: Dr. A. M. Thaker Minor Advisor: Dr. C.G. Joshi Scope The main goals of toxicology include: to elucidate the toxic properties
More informationMike Hinds, Royal Canadian Mint
Experience in the Use of the LBMA Reference Materials Mike Hinds Royal Canadian Mint LBMA Assayer and Refiner March 2011 1 LBMA RM Project 2007-2010 2 Gold Reference Materials AuRM1 and AuRM2 Available
More informationIntroduction to principles of toxicology and risk assessment
Introduction to principles of toxicology and risk assessment SEAC Training Helsinki, 29-30/06/2009 Kimmo Louekari Unit B4, Evaluation Disclaimer: This presentation does not represent ECHA s position on
More informationIs a Maximal Tolerated Dose in Human useful for drug development?
Is a Maximal Tolerated Dose in Human useful for drug development? How to define an acceptable highest dose to be tested? EuFeMED, London Pre-conference Workshop 17-May-2017 Eric Legangneux Philippe Grosjean
More informationHMPWG - Questions and Answers on First safe Dilutions
HMPWG - Questions and Answers on First safe Dilutions A. Comparison of the HMPWG publications Q&A on FSD documents 1-5 (from 12 November 2013) and Q&A 6 (from 5 June 2014) (Before public consultation)
More informationSection 5.3: Preclinical safety data
Section 5.3: Preclinical safety data SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationTracer studies in GSK for Discovery and Development
Tracer studies in GSK for Discovery and Development 3 rd June 2010...a ripple or a wavefront? Graeme Young, DMPK, GlaxoSmithKline R&D, Ware, UK Outline Historical use of AMS at GSK variety of ADME studies;
More informationAbsorption, Distribution, Metabolism, Excretion and Toxicology
Draft Guidance Novel Foods Absorption, Distribution, Metabolism, Excretion and Toxicology Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Stakeholder Meeting, 11 April
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationEU policy on acrylamide in food reducing human exposure to ensure a high level of human health protection
Directorate-General for Health & Food Safety EU policy on acrylamide in food reducing human exposure to ensure a high level of human health protection Frans Verstraete Principles for regulating contaminants
More informationAnnex II. Scientific conclusions and grounds for variation to the terms of the marketing authorisations
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations 13 Scientific conclusions Overall summary of the scientific evaluation of thiocolchicoside containing
More informationOverview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan
1 5 th Joint Conference of Taiwan and Japan on Medical Products Regulation Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan Mr. Yoshihiko Sano Deputy Director,
More informationBENZETHONIUM CHLORIDE
OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING BENZETHONIUM CHLORIDE COLIPA n P 70 adopted by the SCCNFP during the 26 th plenary meeting
More informationChallenges and Strategies to Facilitate Formulation Development of Pediatric Drug Products
Challenges and Strategies to Facilitate Formulation Development of Pediatric Drug Products Session 5: Safety Qualification of Excipients Session Chairs: Darren Fegley (FDA) Lorrene Buckley (Eli Lilly &
More informationGeneral Considerations
The Science of Chemical Safety Essential Toxicology - 1 General Considerations John Duffus & Howard Worth IUPAC Educators Resource Material IUPAC General Considerations Toxicology is the science which
More informationProduct Stewardship Information Sheet CH350LN
Product Stewardship Information Sheet CH350LN Contents Product Manufacturer... 2 Food Contact... 2 European Union (EU) Food Contact... 2 US Food and Drug Administration (FDA)... 2 Canada Health Protection
More informationEFSA Info Session on Applications. Technical meeting on food flavourings applications. Parma, 20 th January 2015
EFSA Info Session on Applications Technical meeting on food flavourings applications Parma, 20 th January 2015 1 TOPICS General procedural & administrative issues Risk assessment challenges of toxicological
More informationSAFETY DATA SHEET BICOWHITE COMPLEX. SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1 Product Identifier BW_S3
Pag. 1/9 SAFETY DATA SHEET SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1 Product Identifier Code 1.2 Relevant identified uses of the substances or mixture and uses
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/815/02-FINAL January 2002 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS COLISTIN SUMMARY REPORT
More informationPublic Assessment Report. Scientific discussion. Risperidon Medartuum film-coated tablets Risperidone SE/H/722/01-06/MR
Public Assessment Report Scientific discussion Risperidon Medartuum film-coated tablets Risperidone SE/H/722/01-06/MR This module reflects the scientific discussion for the approval of Risperidon Medartuum
More informationPublic Assessment Report Scientific discussion. Lamotrigin Medartuum Lamotrigine SE/H/728/01-04/MR
Public Assessment Report Scientific discussion Lamotrigin Medartuum Lamotrigine SE/H/728/01-04/MR This module reflects the scientific discussion for the approval of Lamotrigin Medartuum. The procedure
More informationProduct Stewardship Information Sheet CH200LN-02
Product Stewardship Information Sheet CH200LN-02 Contents Product Manufacturer... 2 Food Contact... 2 European Union (EU) Food Contact... 2 US Food and Drug Administration (FDA)... 2 Canada Health Protection
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) Draft GUIDELINE ON THE SPECIFICATION LIMITS FOR RESIDUES OF METAL CATALYSTS
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) Draft London, January 2007 Doc. Ref. CPMP/SWP/QWP/4446/00 corr. GUIDELINE
More informationActual Excipient Test Data on Metal Impurities Submitted to IPEC-Americas from Industry
Actual Excipient Test Data on Metal Impurities Submitted to IPEC-Americas from Industry Priscilla Zawislak Chair Compendial Review Committee IPEC Americas Global Regulatory Affairs Manager Ashland Inc.
More informationThe study of the adverse effects of a toxicant on living organisms. Principles of Toxicology: The Study of Poisons. Axioms of Toxicology
Principles of Toxicology: The Study of Poisons The study of the adverse effects of a toxicant on living organisms Adverse effects any change from an organism s normal state dependent upon the concentration
More informationSCCNFP/0694/03, final OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING METHYL ACETATE
OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING METHYL ACETATE adopted by the SCCNFP during the 24 th plenary meeting of 24-25 June 2003
More informationGeneral concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale Cathie VIELLE Head of European Pharmacopoeia Department, EDQM / CoE 1 The structure of the Ph. Eur. General monographs Dosage form monographs General
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationTablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good
TABLET PRODUCTİON Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good quality at high standards. Based on preformulation
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationPublic Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC
Public Assessment Report Scientific discussion Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC This module reflects the scientific discussion for the approval of Anastrozole
More informationThe Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05
The Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05 1 TABLE OF CONTENTS Highlights Clinical Trials Narcolepsy Profile Ancillary Pharmacology Mechanism of Action Preclinical Pharmacology
More informationSTUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE
VICH GL54 (SAFETY) ARfD November 2016 For Implementation at Step 7 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH AN ACUTE REFERENCE DOSE (ARfD)
More informationICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals. Step 5
European Medicines Agency March 1998 CPMP/ICH/299/95 ICH Topic S1B Carcinogenicity: Testing for Carcinogenicity of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON CARCINOGENICITY: TESTING FOR CARCINOGENICITY
More informationPublic Assessment Report Scientific discussion. Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC
Public Assessment Report Scientific discussion Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC This module reflects the scientific discussion for the approval of Ciprofloxacin Accord.
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 8 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationPublic Assessment Report Scientific discussion. Ciprofloxacin Pfizer (Ciprofloxacin hydrochloride) SE/H/803/01-03/DC
Public Assessment Report Scientific discussion Ciprofloxacin Pfizer (Ciprofloxacin hydrochloride) SE/H/803/01-03/DC This module reflects the scientific discussion for the approval of Ciprofloxacin Pfizer.
More informationTOXICOLOGY, AND HUMAN HEALTH
TOXICOLOGY, AND HUMAN HEALTH Toxicity measures how harmful a substance is. It mainly depends on dose the amount of absorbed matter. Three types of toxic entities: Chemical Biological Physical Chemicals
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationPublic Assessment Report. Scientific discussion. Pregabalin Orion (pregabalin) SE/H/1440/01-07/DC
Public Assessment Report Scientific discussion Pregabalin Orion (pregabalin) SE/H/1440/01-07/DC This module reflects the scientific discussion for the approval of Pregabalin Orion. The procedure was finalised
More informationAPPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS
SmPC Country: Lebanon Date of approval : 17/08/2011 Procedure : National APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1- NAME OF THE MEDICINAL PRODUCT DECAN, concentrate for solution for infusion 2- QUALITATIVE
More informationAnnex XV. 2,4 - Dinitrotoluene
Annex XV 2,4 - Dinitrotoluene EC Number: 204-450-0 CAS Number: 121-14-2 Proposal for identification of a substance as a CMR cat 1 or 2, PBT, vpvb or a substance of an equivalent level of concern It is
More information